{"id":745024,"date":"2014-03-05T12:15:00","date_gmt":"2014-03-05T12:15:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-hiv-therapy-doravirine-mk-1439-demonstrates-antiviral-activity-in-phase-2b-study-of-treatment-naive-adults\/"},"modified":"2023-03-22T00:04:58","modified_gmt":"2023-03-22T04:04:58","slug":"mercks-investigational-hiv-therapy-doravirine-mk-1439-demonstrates-antiviral-activity-in-phase-2b-study-of-treatment-naive-adults","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-hiv-therapy-doravirine-mk-1439-demonstrates-antiviral-activity-in-phase-2b-study-of-treatment-naive-adults\/","title":{"rendered":"Merck\u2019s Investigational HIV Therapy, Doravirine (MK-1439), Demonstrates Antiviral Activity in Phase 2B Study of Treatment-Na\u00efve Adults"},"content":{"rendered":"<p class=\"bwalignc\">       Merck Plans to Initiate Phase 3 Clinical Development Program in        Second Half of 2014     <\/p>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today presented data from the dose-ranging portion of an ongoing Phase<br \/>\n      2B clinical trial of doravirine, the company\u2019s investigational<br \/>\n      next-generation, non-nucleoside reverse transcriptase inhibitor (NNRTI),<br \/>\n      at the 21<sup>st<\/sup> Conference on Retroviruses and Opportunistic<br \/>\n      Infections (CROI). Interim data demonstrating potent antiretroviral<br \/>\n      (ARV) activity for four doses (25, 50, 100 and 200 mg) of once-daily,<br \/>\n      oral doravirine in combination with tenofovir\/emtricitabine in<br \/>\n      treatment-na\u00efve, HIV-1 infected adults after 24 weeks of treatment were<br \/>\n      presented during a late-breaker oral session. Based on these findings as<br \/>\n      well as other data from the doravirine clinical program, Merck plans to<br \/>\n      initiate a Phase 3 clinical trial program for doravirine in combination<br \/>\n      with ARV therapy in the second half of 2014.\n    <\/p>\n<p>\n      \u201cBuilding on our long-standing commitment to the HIV community, Merck<br \/>\n      continues to evaluate new candidates we believe have the potential to<br \/>\n      make a meaningful difference in the lives of HIV patients,\u201d said Daria<br \/>\n      Hazuda, Ph.D., vice president, Infectious Diseases, Merck Research<br \/>\n      Laboratories. \u201cWe look forward to advancing doravirine into Phase 3<br \/>\n      clinical trials in the second half of 2014.\u201d\n    <\/p>\n<p>\n      <b>Doravirine Clinical Data<\/b>\n    <\/p>\n<p>\n      This randomized, double-blind clinical trial examined the safety,<br \/>\n      tolerability and efficacy of once-daily doravirine (25, 50, 100 and 200<br \/>\n      mg) in combination with once-daily tenofovir\/emtricitabine versus<br \/>\n      efavirenz (600 mg), in treatment-na\u00efve, HIV-1 infected patients. The<br \/>\n      primary efficacy analysis was percentage of patients achieving virologic<br \/>\n      response (&lt; 40 copies\/mL).\n    <\/p>\n<p>\n      At 24 weeks, doravirine doses of 25, 50, 100, and 200 mg showed<br \/>\n      virologic response rates consistent with those observed for efavirenz at<br \/>\n      a dose of 600 mg. All treatment groups showed increased CD4 cell counts.\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\" colspan=\"3\">\n<p class=\"bwcellpmargin\">\n            Proportion of Patients with Virologic<br \/>Response at 24 weeks<br \/>\n            (95% CI)\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            Mean CD4 Change<br \/>from Baseline (95% CI)\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">\n          Treatment*\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          Dose (mg)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          n\/N\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            % &lt;40<br \/>copies\/mL\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            cells\/\u03bcL\n          <\/p>\n<p class=\"bwcellpmargin\">&nbsp;<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">\n          Doravirine\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          25\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          32\/40\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          80.0 (64.6, 90.9)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          158 (119, 197)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          50\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          32\/42\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          76.2 (60.5, 87.9)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          116 (77, 155)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          100\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          30\/42\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          71.4 (55.4, 84.3)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          134 (100, 167)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          200\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          32\/41\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          78.0 (62.4, 89.4)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          141 (96, 186)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">\n          Efavirenz\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          600\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          27\/42\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          64.3 (48.0, 78.4)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          121 (73, 169)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\" colspan=\"3\">\n          Missing data approach:\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\" colspan=\"3\">\n          Non-completer = Failure\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          Observed Failure\n        <\/td>\n<\/tr>\n<tr>\n<td colspan=\"3\">\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td colspan=\"3\">\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\" colspan=\"9\">\n<p class=\"bwcellpmargin\">\n            <i>*In combination with tenofovir\/emtricitabine<\/i>\n          <\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>\n      The incidence of drug-related adverse events was comparable among the<br \/>\n      doravirine-treated groups. The overall incidence of drug-related adverse<br \/>\n      events was lower in the doravirine-treated groups (n=166) than the<br \/>\n      efavirenz-treated group (n=42), 35 percent and 57 percent, respectively.<br \/>\n      The most common central nervous system (CNS) adverse events at week 8,<br \/>\n      the primary time point for evaluation of CNS adverse experiences, were<br \/>\n      dizziness [3.0% doravirine (overall) and 23.8% efavirenz], nightmare<br \/>\n      [1.2% doravirine (overall) and 9.5% efavirenz], abnormal dreams [9.0%<br \/>\n      doravirine (overall) and 7.1% efavirenz], and insomnia [5.4% doravirine<br \/>\n      (overall) and 7.1% efavirenz].\n    <\/p>\n<p>\n      Based on the 24-week data from this dose-finding study, a single dose of<br \/>\n      100 mg doravirine was chosen to be studied for the remainder of this<br \/>\n      study, up to 96 weeks.\n    <\/p>\n<p>\n      <b>About Doravirine<\/b>\n    <\/p>\n<p>\n      Doravirine, also known as MK-1439, is an investigational<br \/>\n      next-generation, NNRTI being evaluated by Merck for the treatment of<br \/>\n      HIV-1 infection. In preclinical studies, doravirine demonstrated potent<br \/>\n      antiviral activity against HIV-1 with a characteristic profile of<br \/>\n      resistance mutations selected <i>in vitro <\/i>compared with currently<br \/>\n      available NNRTIs. In early clinical studies, doravirine demonstrated a<br \/>\n      pharmacokinetic profile supportive of once-daily dosing and did not show<br \/>\n      a significant food effect.\n    <\/p>\n<p>\n      <b>Merck\u2019s Commitment to HIV<\/b>\n    <\/p>\n<p>\n      For more than 25 years, Merck has been at the forefront of the response<br \/>\n      to the HIV epidemic, and has helped to make a difference through our<br \/>\n      proud legacy of commitment to innovation, collaborating with the<br \/>\n      community, and expanding global access to medicines. Merck is dedicated<br \/>\n      to applying our scientific expertise, resources and global reach to<br \/>\n      deliver healthcare solutions that support people living with HIV<br \/>\n      worldwide.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=50817772&amp;newsitemid=20140305006276&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=1&amp;md5=e3457a3983dd0cc49ada59d3c1680c51\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=50817772&amp;newsitemid=20140305006276&amp;lan=en-US&amp;anchor=Twitter&amp;index=2&amp;md5=e9df42021ff386e4bc44d85f390fe639\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=50817772&amp;newsitemid=20140305006276&amp;lan=en-US&amp;anchor=Facebook&amp;index=3&amp;md5=b492fdda7ab73e97fae056a30382aeaf\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=50817772&amp;newsitemid=20140305006276&amp;lan=en-US&amp;anchor=YouTube&amp;index=4&amp;md5=bc20fc811e9fc171f0f88ea4ee78ec85\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2013 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50817772&amp;newsitemid=20140305006276&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=5&amp;md5=79ec15901f564065918dbb2ce0c4d107\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140305006276r1&amp;sid=hq1sf1&amp;distro=nx\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Caroline Lappetito, 267-305-7639<br \/>or<br \/>Sarra        Herzog, 201-669-6570<br \/>or<br \/>Investor:<br \/>Carol Ferguson,        908-423-4465<br \/>or<br \/>Justin Holko, 908-423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck Plans to Initiate Phase 3 Clinical Development Program in Second Half of 2014 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today presented data from the dose-ranging portion of an ongoing Phase 2B clinical trial of doravirine, the company\u2019s investigational next-generation, non-nucleoside reverse transcriptase inhibitor (NNRTI), at the 21st Conference on Retroviruses and Opportunistic Infections (CROI). Interim data demonstrating potent antiretroviral (ARV) activity for four doses (25, 50, 100 and 200 mg) of once-daily, oral doravirine in combination with tenofovir\/emtricitabine in treatment-na\u00efve, HIV-1 infected adults after 24 weeks of treatment were presented during a late-breaker oral session. Based on these findings as well as other data from the doravirine clinical program, Merck plans to initiate a Phase 3 clinical trial program for doravirine in combination with ARV therapy in the second half of 2014. \u201cBuilding on our long-standing commitment to<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-745024","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck\u2019s Investigational HIV Therapy, Doravirine (MK-1439), Demonstrates Antiviral Activity in Phase 2B Study of Treatment-Na\u00efve Adults - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-hiv-therapy-doravirine-mk-1439-demonstrates-antiviral-activity-in-phase-2b-study-of-treatment-naive-adults\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck\u2019s Investigational HIV Therapy, Doravirine (MK-1439), Demonstrates Antiviral Activity in Phase 2B Study of Treatment-Na\u00efve Adults - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck Plans to Initiate Phase 3 Clinical Development Program in Second Half of 2014 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today presented data from the dose-ranging portion of an ongoing Phase 2B clinical trial of doravirine, the company\u2019s investigational next-generation, non-nucleoside reverse transcriptase inhibitor (NNRTI), at the 21st Conference on Retroviruses and Opportunistic Infections (CROI). Interim data demonstrating potent antiretroviral (ARV) activity for four doses (25, 50, 100 and 200 mg) of once-daily, oral doravirine in combination with tenofovir\/emtricitabine in treatment-na\u00efve, HIV-1 infected adults after 24 weeks of treatment were presented during a late-breaker oral session. Based on these findings as well as other data from the doravirine clinical program, Merck plans to initiate a Phase 3 clinical trial program for doravirine in combination with ARV therapy in the second half of 2014. \u201cBuilding on our long-standing commitment to\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-hiv-therapy-doravirine-mk-1439-demonstrates-antiviral-activity-in-phase-2b-study-of-treatment-naive-adults\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:58+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140305006276r1&amp;sid=hq1sf1&amp;distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-hiv-therapy-doravirine-mk-1439-demonstrates-antiviral-activity-in-phase-2b-study-of-treatment-naive-adults\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-hiv-therapy-doravirine-mk-1439-demonstrates-antiviral-activity-in-phase-2b-study-of-treatment-naive-adults\\\/\",\"name\":\"Merck\u2019s Investigational HIV Therapy, Doravirine (MK-1439), Demonstrates Antiviral Activity in Phase 2B Study of Treatment-Na\u00efve Adults - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-hiv-therapy-doravirine-mk-1439-demonstrates-antiviral-activity-in-phase-2b-study-of-treatment-naive-adults\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-hiv-therapy-doravirine-mk-1439-demonstrates-antiviral-activity-in-phase-2b-study-of-treatment-naive-adults\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20140305006276r1&amp;sid=hq1sf1&amp;distro=nx\",\"datePublished\":\"2014-03-05T12:15:00+00:00\",\"dateModified\":\"2023-03-22T04:04:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-hiv-therapy-doravirine-mk-1439-demonstrates-antiviral-activity-in-phase-2b-study-of-treatment-naive-adults\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-hiv-therapy-doravirine-mk-1439-demonstrates-antiviral-activity-in-phase-2b-study-of-treatment-naive-adults\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-hiv-therapy-doravirine-mk-1439-demonstrates-antiviral-activity-in-phase-2b-study-of-treatment-naive-adults\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20140305006276r1&amp;sid=hq1sf1&amp;distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20140305006276r1&amp;sid=hq1sf1&amp;distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-hiv-therapy-doravirine-mk-1439-demonstrates-antiviral-activity-in-phase-2b-study-of-treatment-naive-adults\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck\u2019s Investigational HIV Therapy, Doravirine (MK-1439), Demonstrates Antiviral Activity in Phase 2B Study of Treatment-Na\u00efve Adults\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck\u2019s Investigational HIV Therapy, Doravirine (MK-1439), Demonstrates Antiviral Activity in Phase 2B Study of Treatment-Na\u00efve Adults - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-hiv-therapy-doravirine-mk-1439-demonstrates-antiviral-activity-in-phase-2b-study-of-treatment-naive-adults\/","og_locale":"en_US","og_type":"article","og_title":"Merck\u2019s Investigational HIV Therapy, Doravirine (MK-1439), Demonstrates Antiviral Activity in Phase 2B Study of Treatment-Na\u00efve Adults - Merck.com","og_description":"Merck Plans to Initiate Phase 3 Clinical Development Program in Second Half of 2014 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today presented data from the dose-ranging portion of an ongoing Phase 2B clinical trial of doravirine, the company\u2019s investigational next-generation, non-nucleoside reverse transcriptase inhibitor (NNRTI), at the 21st Conference on Retroviruses and Opportunistic Infections (CROI). Interim data demonstrating potent antiretroviral (ARV) activity for four doses (25, 50, 100 and 200 mg) of once-daily, oral doravirine in combination with tenofovir\/emtricitabine in treatment-na\u00efve, HIV-1 infected adults after 24 weeks of treatment were presented during a late-breaker oral session. Based on these findings as well as other data from the doravirine clinical program, Merck plans to initiate a Phase 3 clinical trial program for doravirine in combination with ARV therapy in the second half of 2014. \u201cBuilding on our long-standing commitment to","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-hiv-therapy-doravirine-mk-1439-demonstrates-antiviral-activity-in-phase-2b-study-of-treatment-naive-adults\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:58+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140305006276r1&amp;sid=hq1sf1&amp;distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-hiv-therapy-doravirine-mk-1439-demonstrates-antiviral-activity-in-phase-2b-study-of-treatment-naive-adults\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-hiv-therapy-doravirine-mk-1439-demonstrates-antiviral-activity-in-phase-2b-study-of-treatment-naive-adults\/","name":"Merck\u2019s Investigational HIV Therapy, Doravirine (MK-1439), Demonstrates Antiviral Activity in Phase 2B Study of Treatment-Na\u00efve Adults - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-hiv-therapy-doravirine-mk-1439-demonstrates-antiviral-activity-in-phase-2b-study-of-treatment-naive-adults\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-hiv-therapy-doravirine-mk-1439-demonstrates-antiviral-activity-in-phase-2b-study-of-treatment-naive-adults\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140305006276r1&amp;sid=hq1sf1&amp;distro=nx","datePublished":"2014-03-05T12:15:00+00:00","dateModified":"2023-03-22T04:04:58+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-hiv-therapy-doravirine-mk-1439-demonstrates-antiviral-activity-in-phase-2b-study-of-treatment-naive-adults\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-hiv-therapy-doravirine-mk-1439-demonstrates-antiviral-activity-in-phase-2b-study-of-treatment-naive-adults\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-hiv-therapy-doravirine-mk-1439-demonstrates-antiviral-activity-in-phase-2b-study-of-treatment-naive-adults\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140305006276r1&amp;sid=hq1sf1&amp;distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140305006276r1&amp;sid=hq1sf1&amp;distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-hiv-therapy-doravirine-mk-1439-demonstrates-antiviral-activity-in-phase-2b-study-of-treatment-naive-adults\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck\u2019s Investigational HIV Therapy, Doravirine (MK-1439), Demonstrates Antiviral Activity in Phase 2B Study of Treatment-Na\u00efve Adults"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"a4dee257-b4f1-4c6c-af36-6fa2bdc9590f","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Mercks-Investigational-HIV-Therapy-Doravirine-MK-1439-Demonstrates-Antiviral-Activity-in-Phase-2B-Study-of-Treatment-Nave-Adults-2014.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745024","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745024\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745024"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745024"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}